Literature DB >> 8808223

Removal of clodronate by haemodialysis in end-stage renal disease patients.

A E Beigel1, E Rienhoff, C J Olbricht.   

Abstract

BACKGROUND: Clodronate is a potent calcium-lowering drug. The effect of haemodialysis on clodronate pharmacokinetics is unknown.
METHODS: The removal of clodronate by haemodialysis was determined in 10 end-stage renal disease patients (ESRD). A 2-h infusion of 300 mg of clodronate was followed immediately by a 4-h haemodialysis. Vascular access was by AV fistula. A 1.5-m2 cuprophane hollow-fibre dialyser was applied. Blood flow was 205 +/- 15 ml/min, dialysate flow 523 +/- 29 ml/min. Clodronate was determined by high-performance liquid chromatography in total collected dialysate, and in blood before and after the dialyser at initiation, 2 h, and 4 h of HD.
RESULTS: The initial predialyser serum concentration of clodronate was 13.6 +/- 4 micrograms/ml. It decreased to 4.9 +/- 0.5 micrograms/ml and 2.6 +/- 0.5 micrograms/ml at 2 h and 4 h respectively. The clearance of clodronate (86 +/- 10 ml/min) remained unchanged during HD. Clodronate in total collected dialysate per single 4-h HD was 105 +/- 16 mg (35% of injected dose).
CONCLUSION: We conclude that clodronate is effectively removed from plasma by HD. The present data together with information provided by previous studies suggest that 300 mg of clodronate given as an 2-h infusion immediately prior to haemodialysis is an adequate dosage for ESRD patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8808223     DOI: 10.1093/ndt/10.12.2266

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  3 in total

Review 1.  Can bisphosphonates play a role in the treatment of children with chronic kidney disease?

Authors:  Dieter Haffner; Dagmar-Christiane Fischer
Journal:  Pediatr Nephrol       Date:  2011-01-27       Impact factor: 3.714

Review 2.  Pharmacology of bisphosphonates.

Authors:  Serge Cremers; Matthew T Drake; F Hal Ebetino; John P Bilezikian; R Graham G Russell
Journal:  Br J Clin Pharmacol       Date:  2019-02-28       Impact factor: 4.335

3.  Bisphosphonate therapy in metastatic carcinoma patients with chronic renal failure: are bisphosphonates an enemy or crony?

Authors:  Fatos Dilan Koseoglu; Cagatay Arslan
Journal:  Support Care Cancer       Date:  2015-03-13       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.